Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on ...

March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...

Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...

In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...